U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.92 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.91 (-0.21%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Silver

    24.39
    +0.22 (+0.91%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.26%)
     
  • USD/JPY

    113.4800
    -0.5080 (-0.45%)
     
  • BTC-USD

    60,450.02
    -798.50 (-1.30%)
     
  • CMC Crypto 200

    1,453.34
    -49.70 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Where COVID-19 vaccines stand following AstraZeneca setback

In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Yahoo Finance's Anjalee Khemlani breaks down the latest in the COVID-19 vaccine race with the On the Move panel.

Video Transcript

ADAM SHAPIRO: Everybody is talking about the potential for a COVID-19 vaccine, and weekly, we get a checkup on where we stand in the race for that, and joining us to bring us up to speed is Anjalee Khemlani with a great deal of news, and some of it not very good, especially when you talk about COVID cases in Europe, right?

ANAJLEE KHEMLANI: That's correct, Adam. We know that we're seeing sort of this resurgence in some parts, very concerning. And also kind of telltale for what experts are saying could be happening in the upcoming seasons this year. Definitely a concern from top experts like Anthony Fauci and NIH Director, Francis Collins. But moving on to the vaccines themselves, we're hearing a lot of different types of news. We know that out of China we got today, the approval of phase 1 trial for a nasal spray vaccine. And that's something that is particularly of interest, because we know that Operation Warp Speed is looking at different delivery methods. On an August 20 call, they did mention that different delivery methods were, in fact, going to be on the table, and the doors not yet closed for additional funding of different vaccines.

Meanwhile, we know about AstraZeneca, right now on pause as we look at the phase 3 trial, the furthest ahead based on an adverse event that was reported. Still unclear, the CEO says, when that will be restarted. But we do know that they anticipate remaining on track for a vaccine by the end of this year. Meanwhile, we know that companies like Pfizer and Moderna also in their phase 3 trials, continue to push ahead, and expecting some news at least of entry of vaccines from other participants by the end of this month and early next month.